<DOC>
	<DOCNO>NCT00737100</DOCNO>
	<brief_summary>This study evaluate effect 12-week treatment two dos tiotropium bromide ( 2.5 mcg q.d . 5 mcg q.d . ) compare placebo administer via Respimat device lung function patient Cystic Fibrosis . The selection optimal dose base bronchodilator efficacy , safety evaluation pharmacokinetic evaluation</brief_summary>
	<brief_title>Safety Efficacy 12-wk Treatment With Two Doses Tiotropium Respimat Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female patient 2 . Diagnosis Cystic Fibrosis ( positive sweat chloride test two identifiable mutation ) 3 . Prebronchodilator FEV1 greater/equal 25 % predict value Exclusion criterion : 1 . Significant history allergy/hypersensitivity 2 . Hypersensitivity study drug 3 . Participation another trial 4 . Female patient pregnant lactate 5 . Female patient childbearing potential 6 . Patients start new medication CF within 4 week screen 7 . Patients know substance abuse 8 . Clinically significant disease CF</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>